InvestorsHub Logo
Followers 24
Posts 501
Boards Moderated 1
Alias Born 03/09/2014

Re: None

Wednesday, 08/12/2020 8:49:02 AM

Wednesday, August 12, 2020 8:49:02 AM

Post# of 42856
Why HGEN gets its EUA for COVID ARDS (h/t MWM) “ Here we show that after the 2019-nCoV infection, CD4+T lymphocytes are rapidly activated to become pathogenic T helper (Th) 1 cells and generate GM-CSF etc. The cytokines environment induces inflammatory CD14+CD16+ monocytes with high expression of IL-6 and accelerates the inflammation. These aberrant and excessive immune cells may enter the pulmonary circulation in huge numbers and play an immune damaging role to causing lung functional disability and quick mortality. Our results demonstrate that excessive non-effective host immune responses by pathogenic T cells and inflammatory monocytes may associate with severe lung pathology. Therefore, we suggest that monoclonal antibody that targets the GM-CSF or interleukin 6 receptor may potentially curb immunopathology caused by 2019-nCoV and consequently win more time for virus clearance.”

https://www.biorxiv.org/content/10.1101/2020.02.12.945576v1